NASH: The Next Untapped Pharma Market Gives Investors Many Options NASH: The Next Untapped Pharma Market Gives Investors Many Options
Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat non-alcoholic steatohepatitis (NASH), a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.Reuters Health Information
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Gastroenterology News Source Type: news
More News: Alcoholism | Fatty Liver Disease (FLD) | Gastroenterology | Hemorrhoids | Liver | Liver Disease | Liver Transplant | Pharmaceuticals | Transplant Surgery | Transplants | Urology & Nephrology